Pediatric prescribing of SSRIs and related antidepressants has expanded substantially over the past two decades. For some children with severe depression or anxiety, these medications can be life-saving, and that needs to be said clearly. But the conversation parents typically have at a 15-minute medication visit often does not match the conversation that exists in the published clinical literature. The gap between the two is where informed consent breaks down. None of what follows is a recommendation against treatment — it’s an argument for fuller disclosure before treatment begins.
The black box warning exists for a reason
In 2004, the FDA placed a black box warning on antidepressants regarding increased risk of suicidal thoughts and behavior in children, adolescents, and young adults. The warning was based on pooled trial data, and subsequent analyses have continued to find a small but real signal in this age group, particularly in the first weeks of treatment or after dose changes. The clinical guidance is not “don’t prescribe” — it is “monitor closely and follow up frequently.” In practice, follow-up cadence varies widely, and many families are not told what specific changes to watch for.
Efficacy in pediatric trials is more modest than parents assume
Meta-analyses of pediatric antidepressant trials have generally shown a smaller effect size in children and adolescents than in adults, with fluoxetine performing best and other SSRIs showing more mixed results. The number needed to treat versus placebo in pediatric depression trials is meaningful but not dramatic. A serious discussion would include both the realistic chance of benefit and the realistic chance of side effects without benefit. Many medication consults compress this into a single sentence.
Side effects in growing brains and bodies are under-discussed
Beyond the suicidality warning, common pediatric side effects include emotional blunting, sleep disturbance, weight changes, gastrointestinal symptoms, and sexual side effects in adolescents — the latter rarely raised in office visits. Discontinuation syndrome, where stopping or missing doses produces flu-like symptoms, irritability, and dysphoria, is well-documented and frequently mistaken for relapse. Long-term data on SSRIs across childhood and adolescent development is thinner than the prescribing volume would suggest, and that uncertainty itself deserves acknowledgment.
Therapy is often more effective and undersupplied
For mild and moderate pediatric depression and anxiety, evidence-based therapies — particularly cognitive behavioral therapy and, for adolescents, interpersonal therapy — have effect sizes comparable to or better than medication, with fewer side effects. The reason medication is often the first intervention is supply-side: there are far more prescribers than child therapists, and medication visits are shorter and more billable. The clinical evidence supports a different default for many cases than the system actually delivers.
The bottom line
Antidepressants can be the right choice for a struggling child, and untreated severe depression carries its own grave risks. The point isn’t refusal — it’s a real conversation: realistic benefit estimates, full side effect disclosure, an explicit monitoring plan, a discussion of therapy options, and a clear plan for how the medication will eventually be evaluated or discontinued. If a clinician won’t have that conversation, it’s reasonable to seek a second opinion. Pediatric mental health is hard, and professional support — including from a child psychiatrist or therapist — genuinely helps.
Leave a Reply